Xeris Biopharma Holdings Inc (NAS:XERS)
$ 1.945 -0.065 (-3.23%) Market Cap: 287.62 Mil Enterprise Value: 479.34 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 08:00PM GMT
Release Date Price: $1.15 (+7.48%)
Unidentified Analyst

Welcome, everyone. Thank you for being here. I'm (inaudible) from JPM. We have with us here today, CEO of Xeris Pharma, Paul Edick.

Paul R. Edick
Xeris Biopharma Holdings, Inc. - Chairman & CEO

Thank you. Welcome, everybody. I'm going to give you the overview on Xeris, and then we'll have a Q&A. Xeris is a growth-oriented biopharma company committed to improving the lives of -- and developing and commercializing assets in both rare and specialty areas. I would remind everyone to pay attention to our forward-looking statements. Investing is always a risk.

Let's start off with an overview of the company. Xeris has a very diversified revenue base. We have 3 marketed assets, all growing. RECORLEV, I'll talk a little bit about. It's in the launch stage. And this year, we have guided to $105 million -- or 2022, we've guided to $105 million to $110 million. We'll finish at the top end of that range.

We have a specialized commercial platform in endocrinology and in neurology, and we'll go into some of the products. Our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot